

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
08 May 2025 (08.05.2025)



(10) International Publication Number
WO 2025/096594 A2

(51) International Patent Classification:

A61K 40/11 (2025.01) A61K 40/42 (2025.01)
A61K 40/30 (2025.01) C12N 15/85 (2006.01)
A61K 40/31 (2025.01) C12N 15/90 (2006.01)

(21) International Application Number:

PCT/US2024/053633

(22) International Filing Date:

30 October 2024 (30.10.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/594,261 30 October 2023 (30.10.2023) US
63/659,501 13 June 2024 (13.06.2024) US

(71) Applicant: ALLOGENE THERAPEUTICS, INC.

[US/US]; 210 East Grand Avenue, South San Francisco,
California 94080 (US).

(72) Inventors: LAURON, Elvin J.; c/o Allogene Therapeutics,
Inc., 210 East Grand Avenue, South San Francisco, Cali-
fornia 94080 (US). PERTEL, Thomas Charles; 15 Corte
Nueva, Millbrae, California 94030 (US). SASU, Barbra
Johnson; 1076 Hampshire Street, San Francisco, Califor-
nia 94110 (US). SOMMER, Cesar Adolfo; c/o Allogene
Therapeutics, Inc., 210 East Grand Avenue, South San Fran-
cisco, California 94080 (US). JIN, Steven W.; c/o Allo-
gene Therapeutics, Inc., 210 East Grand Avenue, South San
Francisco, California 94080 (US). GOPALAKRISHNAN,
Suhasni; c/o Allogene Therapeutics, Inc., 210 East Grand
Avenue, South San Francisco, California 94080 (US). LI,
Zhe; c/o Allogene Therapeutics, Inc., 210 East Grand Av-
enue, South San Francisco, California 94080 (US).

(74) Agent: CHANG, Y. Elaine et al.; c/o Allogene Therapeu-
tics, Inc., 210 East Grand Avenue, South San Francisco,
California 94080 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

- without international search report and to be republished
upon receipt of that report (Rule 48.2(g))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: CELLS EXPRESSING ANTI-CD19 CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE THEREOF

(57) Abstract: The present disclosure relates to DNA constructs encoding a CD19-specific chimeric antigen receptor (CAR) and other recombinant proteins, for example, a CD70-binding protein or a CD70-specific CAR, and engineered immune cells (e.g., CD19-specific CAR T cells or CD19/CD70 dual CAR T cells) comprising the DNA constructs, methods of making the same, and uses thereof in therapeutic applications.

WO 2025/096594 A2